PDUFA Talks: FDA Floats “Information Sharing” Pause In New Review Model
Executive Summary
FDA’s new proposed review model would break the process into four distinct phases and eliminate some extensions of the review deadline, yet the actual review cycle still likely would be lengthened.
You may also be interested in...
FDA Could Answer "Clarifying" Questions, But Only For Firms Without Approved Product
The drug industry is not only worried about vulnerable patients, it's worried about vulnerable companies.
FDA May Require NDA Pre-Filing Meeting Under PDUFA V Review Model; Pilot Launching Soon
The new application review process being negotiated as part of the PDUFA V reauthorization is nearing the pilot stage and could require sponsors to have the bulk of their information ready before submission.
FDA Could Answer "Clarifying" Questions, But Only For Firms Without Approved Product
The drug industry is not only worried about vulnerable patients, it's worried about vulnerable companies.